Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
DIOSynVax logo — Innovation in Vaccine Antigen Design

DIOSynVax

Innovation in Vaccine Antigen Design

Founded 2017 United Kingdom Cambridge, United Kingdom 22 employees Grant Total: $45.40M Biotechnology, Information Technology

General Information

Company Name DIOSynVax
Founded Year 2017
Location United Kingdom Cambridge, United Kingdom
Employees 22
Industries Biotechnology, Information Technology
Funding Stage Grant
Social

BounceWatch is an independent company data service, not affiliated with DIOSynVax. To contact DIOSynVax, visit diosvax.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does DIOSynVax compare?

A PDF of DIOSynVax and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting DIOSynVax soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About DIOSynVax

DIOSynVax is a UK-based biotech startup focused on transforming the way the world defends itself against infectious diseases and emerging pathogens. The company's proprietary technology, DIOSynVax (Digitally designed, Immune Optimised Selected and Synthesized Vaccines), stands at the core of their mission. This innovative system aims to expedite vaccine development while significantly enhancing protection against emerging and re-emerging pathogens. Founded in 2017, DIOSynVax operates at the intersection of Biotechnology and Information Technology. The startup recently secured a substantial $42.00M grant investment from the Coalition for Epidemic Preparedness Innovations in March 08, 2022. This funding injection is expected to fuel the company's research and development efforts, potentially propelling their groundbreaking technology into the forefront of vaccine innovation. Overall, DIOSynVax's commitment to leveraging advanced technology to address global health challenges positions them as a promising player in the biotech landscape, especially as the world grapples with the need for swift and effective responses to emerging infectious threats. With noteworthy financial backing and a compelling vision, DIOSynVax holds the potential to significantly impact the future of vaccine development and global health security.

Business keywords: biotech startup, vaccine development, infectious disease, pathogen protection, vaccine technology, immune optimization, digital antigen design, emerging pathogens, immunization innovation

Funding Rounds & Investors (3)

View All
Funding Stage Amount Investors Lead Investors Date
Grant $42.00M 1
Coalition for Epidemic Preparedness Innovations
Coalition for Epidemic Preparedness Innovations
08 Mar 2022
Grant £1.90M 1
Innovate UK
Innovate UK
26 Aug 2020
Seed Round £1.50M 1
Parkwalk Advisors
Parkwalk Advisors
21 Jan 2020

DIOSynVax Alternatives & Competitors

View All Alternatives
DIOSynVax vs
Aviex Technologies LLC
Aviex Technologies LLC United States

Aviex Technologies LLC was founded to develop a novel vaccine platform delivery technology for infec...

3 employees
Biotechnology, Information Technology
DIOSynVax vs
Alchemy
Alchemy Canada

Transforming Conversations to Code

113 employees
Biotechnology, Information Technology
DIOSynVax vs
NTP Nano Tech Projects srl
NTP Nano Tech Projects srl Italy

La nostra tecnologia, risultato della ricerca e della curiosità

Seed
11 employees
Biotechnology, Health Care
View all alternatives

FAQ About DIOSynVax

Innovation in Vaccine Antigen Design
DIOSynVax was founded in 2017.
DIOSynVax is headquartered in Cambridge, United Kingdom.
DIOSynVax operates in Biotechnology and Information Technology. Its work centres on biotech startup, vaccine development, infectious disease and pathogen protection.
DIOSynVax has approximately 22 employees.
DIOSynVax has completed 3 funding rounds, raising a total of $45.40M. The latest funding stage is Grant.
Top alternatives and competitors to DIOSynVax include Aviex Technologies LLC, Alchemy, NTP Nano Tech Projects srl. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
DIOSynVax and Aviex Technologies LLC are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for DIOSynVax, https://bouncewatch.com/company/diosynvax, updated 18 November 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout